全文获取类型
收费全文 | 2872175篇 |
免费 | 216282篇 |
国内免费 | 29651篇 |
专业分类
耳鼻咽喉 | 37034篇 |
儿科学 | 88244篇 |
妇产科学 | 76105篇 |
基础医学 | 399067篇 |
口腔科学 | 74718篇 |
临床医学 | 275776篇 |
内科学 | 555467篇 |
皮肤病学 | 65144篇 |
神经病学 | 229715篇 |
特种医学 | 111073篇 |
外国民族医学 | 948篇 |
外科学 | 415543篇 |
综合类 | 98962篇 |
现状与发展 | 81篇 |
一般理论 | 983篇 |
预防医学 | 212981篇 |
眼科学 | 65547篇 |
药学 | 218447篇 |
335篇 | |
中国医学 | 22556篇 |
肿瘤学 | 169382篇 |
出版年
2021年 | 35430篇 |
2020年 | 24143篇 |
2019年 | 30981篇 |
2018年 | 40128篇 |
2017年 | 32061篇 |
2016年 | 35047篇 |
2015年 | 43173篇 |
2014年 | 57443篇 |
2013年 | 74915篇 |
2012年 | 101682篇 |
2011年 | 108888篇 |
2010年 | 66128篇 |
2009年 | 60766篇 |
2008年 | 94961篇 |
2007年 | 99699篇 |
2006年 | 101564篇 |
2005年 | 97575篇 |
2004年 | 88583篇 |
2003年 | 85135篇 |
2002年 | 81153篇 |
2001年 | 134401篇 |
2000年 | 138223篇 |
1999年 | 118397篇 |
1998年 | 36379篇 |
1997年 | 33137篇 |
1996年 | 32358篇 |
1995年 | 31157篇 |
1994年 | 28140篇 |
1993年 | 25380篇 |
1992年 | 87525篇 |
1991年 | 83574篇 |
1990年 | 80525篇 |
1989年 | 77550篇 |
1988年 | 70740篇 |
1987年 | 69007篇 |
1986年 | 64383篇 |
1985年 | 61183篇 |
1984年 | 45276篇 |
1983年 | 38142篇 |
1982年 | 22553篇 |
1979年 | 39058篇 |
1978年 | 27423篇 |
1977年 | 23226篇 |
1976年 | 21470篇 |
1975年 | 22805篇 |
1974年 | 26819篇 |
1973年 | 25383篇 |
1972年 | 23789篇 |
1971年 | 21972篇 |
1970年 | 20198篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
101.
Madan M. Rehani Emily R. Melick Raza M. Alvi Ruhani Doda Khera Salma Batool-Anwar Tomas G. Neilan Michael Bettmann 《European radiology》2020,30(4):1839-1846
To determine percent of patients without malignancy and ≤ 40 years of age with high cumulative radiation doses through recurrent CT exams and assess imaging appropriateness. From the cohort of patients who received cumulative effective dose (CED) of ≥ 100 mSv over a 5-year period, a sub-set was identified with non-malignant disease. The top 50 clinical indications leading to multiple CTs were determined. Clinical decision support (CDS) system scores were analyzed using a widely adopted standard of 1–3 (red) as “not usually appropriate,” 4–6 (yellow) “may or may not be appropriate,” and 7–9 (green) “usually appropriate.” Clinicians reviewed patient records to assess compliance with appropriate use criteria (AUC). 9.6% of patients in our series were with non-malignant conditions and 1.4% with age ≤ 40 years. CDS scores (rounded) were 2% red, 38% yellow, 27% green, and 33% unscored CTs. Clinical society guidelines for CT exams, wherever available, were followed in 87.5 to 100% of cases. AUCs were not available for several clinical indications as also referral guidelines for serial CT imaging. More than half of CT exams were unrelated to follow-up of a primary chronic disease. We are faced with a situation wherein patients in age ≤ 40 years require or are thought to require many CT exams over the course of a few years but the radiation risk creates concern. There is a fair number of conditions for which AUC are not available. Suggested solutions include development of CT scanners with lesser radiation dose and further development of appropriateness criteria. 相似文献
102.
目的总结不同类型硬膜下积液治疗经验。
方法对解放军总医院第六医学中心神经外科自2009年1月至2014年10月手术治疗并完整随访的27例硬膜下积液患者进行回顾性分析。根据术前影像学特征鉴别积液是否为血性,将患者分为血性硬膜下积液患者(9例)和非血性硬膜下积液患者(18例)。根据积液是否为血性选择个性化治疗方案,观察其疗法。
结果9例血性硬膜下积液患者接受钻孔外引流手术,8例积液消退,另外1例无效,之后接受硬膜下腹腔分流后治愈。非血性硬膜下积液患者中14例接受硬膜下腹腔分流,12例有效,2例术后出现脑积水,经脑室-腹腔分流术治愈;2例术前合并脑积水接受脑室-腹腔分流术,均有效;另外2例最初接受积液外引流,无效,之后行硬膜下腹腔分流后积液消退。
结论对于硬膜下积液患者,术前需仔细评估积液是否为血性,是否合并脑积水。血性积液采取钻孔外引流,非血性积液采取硬膜下腹腔分流,合并脑积水的积液采取脑室-腹腔分流手术方式,给予个体化治疗,可获得满意疗效。 相似文献
103.
104.
目的 初步评估IMRT对无法手术ⅣA期胸腺瘤的疗效及安全性。方法 回顾分析2010-2017年间15例无法手术接受IMRT的ⅣA期胸腺瘤患者,其中男9例、女6例,中位数59岁。PTV、CTV、GTV放疗剂量分别为50、60、70Gy分15~20次,分析近期疗效、总生存率及不良反应。结果 中位随访时间48个月,近期部分缓解率93%(14/15),1、3、5年总生存率分别为100%、75%、75%,仅1例出现3级血液系统反应。4例死亡患者均为肿瘤相关死亡。结论 初步证明ⅣA期胸腺瘤IMRT疗效较好、安全性高,可作为无法手术治疗的胸腺瘤患者安全、有效的治疗手段。 相似文献
105.
Jingjing He Lingyi Zhang Dan Guo Xingwen Han Hui Zhang Liang Wang Youcheng
Zhang 《Oncologie》2020,22(1):1-12
Hepatocellular carcinoma (HCC) ranks the sixth place of most common
cancers. Meanwhile, it is the tertiary mortality cause of cancer. There is no
effective therapeutic method to prevent and treat the liver cancer. Sinomenine is a
kind of Chinese traditional medicine herbal, it is reported that it can inhibit the
viability of several cancer cells. The study is to explore whether sinomenine is also
able to inhibit the cell viability of HCC and its potential mechanism. The IC50 of
sinomenine in BEL-7402 cells was 5.351 mmol/L, and the IC50 of sinomenine in
SMMC-7721 cells was 6.204 mmol/L. The gene expression results showed the
relative expression of FGF2, CCND2, DCN, F3, MMP7, NRG1, HMGB1,
TRIM29, HAS2, EHF, CTGF, PLK2 were down-regulated, and the relative
expression of VEGF A, CITED2, NUPR1, DDX58, IRF9, NAMPT, MMP1,
NDRG1, HMGA2, PPARGC1A, IFIT2, PARP9, HEY1, LOX, ETV1, ISG15,
BACH, CYLD were up-regulated. Moreover, the IPA analysis results suggested
that IFIT3, IFIT1, OAS1, MX1, IRF9, IFI6, IFITM1, ISG15 were up-regulated in
BEL-7402 cells treated with sinomenine by activating IFNA2. The findings
presented in this study may provide a promising method for the prevention and
treatment of liver cancer. 相似文献
106.
107.
目的探讨雨课堂在临床流行病学教学中的作用和效果。方法采用随机对照法在本科阶段无流行病学学习经历的临床专业硕士研究生中,使用雨课堂线上课前预习及课后随堂练习的功能,用于评价雨课堂线上功能的辅助教学效果。结果应用雨课堂线上功能干预组与对照组在基线、阶段小测和末考卷面成绩均无统计学差异;但对于主动学习,雨课堂参与度较高的学生成绩提高明显。结论雨课堂有利于理论性较强课程的学习,但是仍不能忽略课堂教学师生互动过程。 相似文献
108.
109.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
110.
Bo Cai Qiyun Sun Jianhui Qiao Changlin Yu Kaixun Hu Tieqiang Liu Bingxia Li Yajing Huang Yi Wang Hongli Zuo Zheng Dong Yaqing Lei Zhiqing Liu Bo Yao Caixia Li Huisheng Ai Mei Guo 《American journal of cancer research》2020,10(11):3852
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL. 相似文献